Tajirui focuses on originator innovation in targeted oncology drug discovery, aiming to address unmet clinical needs and overcome cancer drug resistance. Its pipeline includes multiple anti-tumor candidates for hematologic malignancies such as chronic myeloid leukemia and solid tumors including non-small cell lung cancer. Two core products, the next-generation Bcr-Abl allosteric inhibitor TGRX-678 and an international‑leading ALK/ROS1 dual inhibitor TGRX-326, entered first-in-human Phase I trials and have completed first subject dosing at Peking University People’s Hospital and Sun Yat-sen University Cancer Center, with clinical progress reported as smooth. The company plans to use newly raised funds to advance key clinical trials for TGRX-678 and TGRX-326 and to develop other First-in-Class and Best-in-Class global innovation projects. In addition to the two core assets, two more novel small-molecule drugs from Tajirui’s pipeline are expected to enter IND filing this year. Financially, Tajirui has previously completed a strategic financing in September 2020 of nearly ¥100 million, with Hongtai Fund contributing tens of millions yuan. Founded in 2014 and based in Shenzhen, 深圳市塔吉瑞生物医药有限公司 is a Sino‑US joint‑venture focused on discovering and developing small‑molecule targeted anti‑tumor drugs that reverse resistance. The company’s pipeline includes candidates for chronic myeloid leukemia (CML) and non‑small cell lung cancer (NSCLC), with TGRX‑678 and TGRX‑326 poised to enter clinical trials. TGRX‑326 is described as a third‑generation ALK inhibitor designed to overcome existing resistance mechanisms and capable of penetrating the blood‑brain barrier.塔吉瑞 has filed over 180 patents across China, the U.S., Europe and Japan, with 39 patents already granted. The recent financing will fund clinical research for its CML and NSCLC small‑molecule programs and support R&D of other next‑generation targeted drugs. The company’s founder, Dr. Wang Yihan, spent 16 years at Ariad Pharmaceuticals and is listed as a core inventor on multiple international first‑in‑class drugs.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2020